摘要
目的对比研究紫杉醇联合顺铂双周方案与三周方案治疗晚期非小细胞肺癌的疗效及不良反应。方法双周方案组：41例晚期非小细胞肺癌患者，给予紫杉醇12Omg／m^2，d1;，顺铂6Omg／m^2，d1，每14天重复，至少用4周期以上评价疗效。三周方案组：40例患者，给予紫杉醇175mg／m^2，d1、d8，顺铂50mg／m2，d1、d2，每21天重复1次。至少用2周期以上评价疗效。结果81例均可评价疗效，双周方案组：三周方案组：有效率48．7％（20／41例）：45．0％（18／40例），中位生存时间43．7周：41．3周，一年生存率43．9％（18／41例）：42．5％（17／40例）。毒副反应方面，Ⅲ～Ⅳ白细胞下降、Ⅲ—Ⅳ血小板下降、Ⅲ—Ⅳ恶心呕吐双周方案组：三周方案组分别为12．2％：27．5％、19．5％：32．5％、7．3％：32．5％；双周方案与三周方案的对比，白细胞下降和恶心呕吐的发生率均有明显减少。结论紫杉醇联合顺铂双周方案与三周方案治疗非小细胞肺癌的疗效大致相等，不良反应明显减少。
Objective To contrast the effect and the adverse effects of Docetaxel plus Cisplatin semimonthly therapy with that of triweekly therapy in advanced nonsmall-cell lung cancer（NSCLC）.Methods Semimonthly therapy group：41 patients of advanced NSCLC were treated with Docetaxel 120mg/m^2 dl, Cisplatin 60mg/m^2, dl .The two regimens were repeated every two weeks and normally at least four cycles . The evaluation is performed two weeks after the completion of chemotherapy. Triweekly therapy group： 40 patients of advanced NSCLC were treated with Docetaxel 175mg/m^2 dl, Cisplatin 50mg/m^2 , d1, d2. The two regimens were repeated every 21 days and normally at least two cycles . Results 81 patients had evaluable lesions. The CR ＋PR rate of semimonthly therapy group is 48. 6%, MST is 34.1 weeks, one-year survival rate is 34.4%. The CR ＋PR rate of triweekly therapy group is 43.7%,MST is 33.3weeks ,one-year survival rate is 34.4%.In semimonthly therapy group ,the incidence of Ⅲ-Ⅳ grade leukopenia is 8.6%, the incidence of Ⅲ-Ⅳ grade haematoblast decrease is 14.3%, the incidence of Ⅲ-Ⅳ grade GI discomfort is 5.7%. In triweekly therapy group ,the incidence of Ⅲ-Ⅳ grade leukopenia is 15.6%, the incidence of Ⅲ-Ⅳ grade haematoblast decrease is 18.8%, the incidence of Ⅲ-Ⅳ grade GI discomfort is 15.6%. Conclusions The efficacy of Docetaxel plus Cisplatin semimonthly therapy is the same as that of triweekly therapy in advanced stage NSCLC. The former has less adverse effect than that of the latter.
出处
《国际医药卫生导报》
2007年第8期55-58,共4页
International Medicine and Health Guidance News
关键词
非小细胞肺癌
紫杉醇
顺铂
Advanced stage nonsmall-cell lung cancer Docetaxel Gisplatin
